Creating a model to predict nerve damage from cancer treatment
Official title: Development of an Integrated Risk Prediction Model of Taxane-induced Peripheral Neuropathy
Funded at University of Michigan at Ann Arbor · NIH-11023126 · Data updated 2026-11-12
This study is looking to create a helpful tool that can predict which cancer patients might experience nerve damage from taxane chemotherapy, so doctors can better tailor treatments to keep you feeling your best while fighting cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $544,768 |
| NIH project number | 5R37CA277043-03 |
| Project ID | NIH-11023126 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients undergoing treatment with taxane chemotherapy who are at risk of developing peripheral neuropathy.
✕Less likely to help
Patients who are not receiving taxane chemotherapy or those who do not experience peripheral neuropathy may not benefit from this research.
What this research studies
This research aims to develop a risk prediction model for taxane-induced peripheral neuropathy (TIPN), a side effect of certain cancer treatments that can severely impact daily living. By analyzing a large group of patients treated with taxane chemotherapy, the study will identify biomarkers that can predict which patients are at higher risk for developing TIPN. The approach involves collecting biospecimens and detailed data on patients' experiences with TIPN to create a clinically useful prediction tool. This model could help tailor chemotherapy treatments to minimize the risk of nerve damage while maximizing cancer treatment effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to better management of chemotherapy side effects, improving patients' quality of life and treatment outcomes.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for chemotherapy side effects, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Hertz, Daniel Louis — University of Michigan at Ann Arbor
- Study coordinator: Hertz, Daniel Louis
Related research
Other NIH-funded projects on the same topics.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Novel pain biomarker for neuropathy that could guide therapy
A study to develop and test a biomarker that reflects how well peripherally acting pain medicines work for people with painful peripheral neuropathy.
-
Auricular vagus nerve stimulation to help HIV-related nerve pain in older adults
A new, non-invasive brain-nerve stimulation approach is being tested to help older adults living with HIV who have nerve pain.
-
Longitudinal study of how body-sense relates to chemotherapy nerve damage
This study follows people with breast or gastrointestinal cancer and healthy controls to see if brain processing of body sensations contributes to chemotherapy-induced nerve damage.
-
Understanding how early nerve excitement during chemotherapy leads to painful nerve damage
A cancer treatment study looks at why the nerve pain some patients get after paclitaxel may develop, by studying how nerves react during the infusion.
-
A new screen for chemotherapy-related nerve problems in young children
A clinician-scientist at Yale is developing a child-friendly survey to quickly screen for nerve-related side effects from cancer treatment in kids from birth to age 5.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.